This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Sep;25(9):465-74.

doi: 10.1097/FPC.0000000000000158.

PharmGKB summary: peginterferon-α pathway

Scott R Shuldiner¹, Li Gong, Andrew J Muir, Russ B Altman, Teri E Klein

Affiliations

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.

PMID: 26111151
PMCID: PMC4757589
DOI: 10.1097/FPC.0000000000000158

PharmGKB summary: peginterferon-α pathway

Scott R Shuldiner et al. Pharmacogenet Genomics. 2015 Sep.

. 2015 Sep;25(9):465-74.

doi: 10.1097/FPC.0000000000000158.

Authors

Scott R Shuldiner¹, Li Gong, Andrew J Muir, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.

PMID: 26111151
PMCID: PMC4757589
DOI: 10.1097/FPC.0000000000000158

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

R.B.A. and T.E.K. are stockholders in Personalis Inc. For the remaining authors, there are no conflicts of interest.

Figures

Fig. 1 — Fig. 1
Stylized depiction of the pharmacodynamics of Peginterferon-α in hepatocytes. A fully interactive version is available at PharmGKB (http://www.pharmgkb.org/pathway/PA166126086).

See this image and copyright information in PMC

Similar articles

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF. Torres-Cornejo A, et al. J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17. J Viral Hepat. 2014. PMID: 24438679
Clinical utility of interleukin-28B testing in patients with genotype 1.
Lai M, Afdhal NH. Lai M, et al. Hepatology. 2012 Jul;56(1):367-72. doi: 10.1002/hep.25793. Hepatology. 2012. PMID: 22511388 Review. No abstract available.
IL28B: A new wager in the skyline of hepatitis C virus infection.
Mangia A. Mangia A. Dig Liver Dis. 2011 Mar;43(3):177-9. doi: 10.1016/j.dld.2010.12.005. Epub 2011 Jan 14. Dig Liver Dis. 2011. PMID: 21237729 No abstract available.
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y. Ishiguro H, et al. World J Gastroenterol. 2015 Apr 7;21(13):3904-11. doi: 10.3748/wjg.v21.i13.3904. World J Gastroenterol. 2015. PMID: 25852275 Free PMC article.
Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, Fagiuoli S. Bruno R, et al. J Viral Hepat. 2012 Jan;19 Suppl 1:33-6. doi: 10.1111/j.1365-2893.2011.01519.x. J Viral Hepat. 2012. PMID: 22233411 Review.

See all similar articles

References

1. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70:147–165. - PubMed
1. [Accessed 28 April 2015];Hepatitis C WHO fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/
1. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164–2170. - PMC - PubMed
1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–S29. - PubMed
1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources